US considers shortening marketing exclusivity to push forward USMCA

The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 From record-breaking litigation wins to billion-dollar deals and global policy leadership, this year’s cohort features the women shaping the future of intellectual property law.

Pharma

What’s at stake in Australia’s biggest pharma patent appeal in years?

1 July 2026 Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.

Pharma

US life sciences damages averaged $33.5m between 2019-2025

18 June 2026 Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

More features

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

US considers shortening marketing exclusivity to push forward USMCA

More on this story

Editor's picks

Editor's picks

More features